Neuropeptide Modulation in Osteoarthritis Pathophysiology

Osteoarthritis (OA) is characterised not only by mechanical wear of cartilage but also by a complex interplay of neural and inflammatory factors. Neuropeptides such as calcitonin gene-related peptide (CGRP) and substance P (SP) are released from peripheral sensory fibres and act on resident joint cells to influence pain perception, synovial inflammation and subchondral bone remodelling. These mediators bind to specific G-protein-coupled receptors or receptor-activity modifying proteins on chondrocytes, synoviocytes and osteoclast precursors, modulating cytokine release, matrix-degrading enzyme expression and osteoclastogenesis. Dysregulation of neuropeptide signalling contributes both to chronic pain and to structural alteration of the joint, promoting cartilage catabolism and aberrant bone sclerosis. Therapeutic strategies that target receptor antagonism, modulate neuropeptide expression or harness cell-based delivery of neuropeptides are emerging as promising approaches to slow disease progression, relieve pain and restore joint homeostasis.

Research from Nature Portfolio

Recent studies have demonstrated that pharmacological blockade of CGRP receptors can suppress OA progression and alleviate pain. In murine models of surgical joint destabilisation and age-related bone sclerosis, systemic administration of a CGRP receptor antagonist reduced synovial inflammation, cartilage degradation and subchondral bone thickening. Treated animals exhibited improved locomotor behaviour and lower levels of CGRP in dorsal root ganglia, without observable adverse effects. These findings highlight CGRP signalling as a critical driver of both nociceptive sensitisation and pathological bone remodelling in OA and support receptor antagonism as a viable disease-modifying strategy.

Neuropeptide Modulation in Osteoarthritis Pathophysiology publication trend

The graph below shows the total number of articles in neuropeptide modulation in osteoarthritis pathophysiology across all publications each year (not limited to Nature Index journals).

Technical terms

Neuropeptide: A small, protein-like molecule released by nerve endings that modulates neuronal and non-neuronal cell function.

Calcitonin gene-related peptide (CGRP): A 37-amino-acid neuropeptide involved in vasodilation, pain transmission and bone remodelling.

Substance P (SP): An 11-amino-acid neuropeptide that promotes inflammation, pain signalling and trophic effects on joint tissues.

Synovitis: Inflammation of the synovial membrane, marked by hyperplasia of synoviocytes and infiltration of immune cells.

Subchondral bone sclerosis: Pathological hardening and thickening of the bone layer beneath articular cartilage, often seen in OA.

References

1. Effects of intra-articular applied rat BMSCs expressing alpha-calcitonin gene-related peptide or substance P on osteoarthritis pathogenesis in a murine surgical osteoarthritis model. Stem Cell Research & Therapy (2025).
2. The dual pro-inflammatory and bone-protective role of calcitonin gene-related peptide alpha in age-related osteoarthritis. Arthritis Research & Therapy (2023).
3. Feasibility of administration of calcitonin gene-related peptide receptor antagonist on attenuation of pain and progression in osteoarthritis. Scientific Reports (2023).
4. Activation of calcitonin gene-related peptide signaling through the prostaglandin E2-EP1/EP2/EP4 receptor pathway in synovium of knee osteoarthritis patients. Journal of Orthopaedic Surgery and Research (2016).